Showing results (451-460 of 548) with videos related to
Sort By:
Pageof 55
Blood|September 2, 2020
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphomaPhilippe Armand, Ann Janssens, Giuseppe Gritti, et al.The Lancet. Haematology|May 30, 2020
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trialGita Thanarajasingam, John P Leonard, Thomas E Witzig, et al.British Journal of Haematology|April 14, 2016
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704Soham D Puvvada, Patrick J Stiff, Michael Leblanc, et al.The Lancet. Haematology|March 19, 2017
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trialsSonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie Ketas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaMyron S Czuczman, Aron Thall, Thomas E Witzig, et al.Cancer Discovery|August 2, 2014
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphomaDavid Chiron, Maurizio Di Liberto, Peter Martin, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE studyA Goy, S H Bernstein, B S Kahl, et al.The American Journal of Surgical Pathology|November 2, 2020
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological TherapyAliyah R Sohani, Matthew J Maurer, Sharmila Giri, et al.Leukemia & Lymphoma|April 16, 2014
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomabRebecca L Elstrom, Jia Ruan, Paul J Christos, et al.Pageof 55